Morbid obesity is a barrier to kidney transplantation due to inferior outcomes, including higher rates of new-onset diabetes after transplantation (NODAT), delayed graft function (DGF), and graft failure. Laparoscopic sleeve gastrectomy (LSG) increases transplant eligibility by reducing BMI in kidney transplant candidates, but the effect of surgical weight loss on posttransplantation outcomes is unknown. Reviewing singlecenter medical records, we identified all patients who underwent LSG before kidney transplantation from 2011-2016 (n = 20). Post-LSG kidney recipients were compared with similar-BMI recipients who did not undergo LSG, using 2:1 direct matching for patient factors. McNemar's test and signed-rank test were used to compare groups.
Laparoscopic sleeve gastrectomy (LSG) is an effective method of weight loss for improving transplant candidacy in this population. 12 Bariatric surgery has also been shown to ameliorate diabetes mellitus (DM) and alleviate cardiovascular risk factors, further optimizing these patients for surgery. 12 The overall impact of LSG on outcomes after transplantation, however, is unknown. In the current study, we examined the effect of LSG on posttransplantation outcomes among morbidly obese kidney transplant recipients. We hypothesized that morbidly obese patients undergoing LSG to meet weight-based criteria for kidney transplantation would have similar or improved posttransplantation outcomes as compared to patients who did not undergo bariatric surgery before transplantation. Primary endpoints were DGF, NODAT, obesity-associated conditions, allograft survival, and patient survival.
| MATERIALS AND METHODS

| Data collection
A retrospective cohort study was performed for all patients who underwent LSG at our institution between December 1, 2011, and May 1, 2016. Institutional bariatric and transplant surgery datasets were linked using patient identifiers. All patients who underwent both LSG and kidney transplantation during the study period were included, and any patients who underwent transplantation before LSG were removed from the final cohort. The bariatric surgery database included data on patient demographics, perioperative outcomes, baseline BMI, and BMI at all subsequent follow-up visits. All patients included in the bariatric dataset had documented inability to achieve significant weight loss through a medical regimen over 6 months, and met the 1991 National Institutes of Health criteria for bariatric surgery (BMI ≥ 40 kg/m 2 , or ≥ 35 kg/m 2 with two or more obesity-related conditions). 13 The renal transplant database included data on etiology of renal failure, donor characteristics, immunosuppression profiles, perioperative outcomes, and long-term outcomes.
Our linked dataset was organized according to date of transplantation. The following patient characteristics were obtained: sex, race, age at LSG, age at kidney transplantation, etiology of kidney disease, and presence of medical comorbidities. Hospital kidney transplantation outcomes analyzed include total hospital length of stay (LOS), perioperative complications, NODAT, DGF, long-term graft survival, 30-day and 1-year readmission rates, and posttransplantation mortality.
| Definitions
The LSG group comprised obese patients who underwent sleeve gastrectomy to meet weight-based criteria for kidney transplantation. The control group comprised matched kidney transplant recipients who did not require surgical weight-loss procedures. DGF was defined as need for dialysis within the first 7 postoperative days. 14 NODAT was defined as new-onset insulin requirements after transplantation. 15 Creatinine clearance (CrCl) was used to estimate renal allograft function after kidney transplantation, and was calculated using the Cockcroft-Gault formula 16 :
| LSG procedure
All LSG procedures were performed by a single surgeon (TSD) who is fellowship trained in both transplantation and minimally invasive surgery. LSG was performed as described previously. 12 Briefly, access was gained into the abdomen through the Hasson technique. After laparoscopic dissection and mobilization of the stomach, we introduced a 38-French bougie and positioned it along the lesser curvature of the stomach. An Endo-GIA stapler (Ethicon Endo-Surgery, Inc., Cincinnati, OH) was used to perform the gastrectomy, with repeated applications from 6 cm proximal to the pylorus to 1.5 cm lateral to the angle of His.
The staple line was not reinforced, and the total resected specimen was approximately 60-80% of the total gastric volume. All patients followed our standard postoperative clinical care protocol, which is reported in the literature.
due to DM (45%) and hypertension (35%), followed by polycystic kid- , P = NS). These data confirm that the 2:1 direct-matching analysis allowed for proper identification of a control group with regard to patient factors.
| Effects of sleeve gastrectomy on BMI and obesity-associated conditions
Post-LSG outcomes are highlighted in Table 2 . This high-risk group did not experience any 30-day readmissions, complications, or mortality following their bariatric procedure. The average hospital LOS was 2.2 ± 0.8 days. The effect of LSG on comorbidities was most pronounced with regard to blood pressure. Among the post-LSG group, 90% were hypertensive prior to their bariatric procedure, which decreased to 60%
immediately before kidney transplantation (Figure 1 ). At most recent follow-up, this percentage further decreased to 40%, and 15% of patients are currently prescribed midodrine for hypotension. Among the control group, a significantly higher proportion of patients were hypertensive before kidney transplantation (90% vs 60%, P < .01).
Posttransplantation rates of hypertension were also higher among controls (82.5% vs 40%, P < .01).
The effects of LSG on glycemic control were less pronounced.
In the post-LSG group, the proportion of patients with diabetes decreased from 60% prior to LSG, to 40% at the time of transplantation. As compared to controls, the rates of diabetes mellitus before kidney transplantation (55% vs 40%) and at most recent follow-up visit (52.5% vs 40%) were similar between groups (P = NS each). No patients developed NODAT in the post-LSG group; however, there were no statistically significant difference in rates of NODAT between post-LSG and control patients (15.8% vs 0%, P = NS). higher among the control group (27.5% vs 10%, P < .05). Rates of DGF were also higher in the control group (20% vs 5%, P < .05), Table 5 . 
| Effects of sleeve gastrectomy on posttransplantation outcomes
| DISCUSSION
T A B L E 4 Outcomes following kidney transplantation
Control KT Mean ± SD, n (%)
Post-LSG KT Mean ± SD, n (%) P-value T A B L E 5 Immunosuppression regimen in the study group all patients can demonstrate adequate oral intake prior to hospital discharge. We also remain in contact with patients' nephrologists and dialysis centers, to ensure that they are not being overdialyzed and receiving appropriate intravenous hydration when necessary. Therefore, LSG improves transplant candidacy among morbidly obese patients with ESRD in a safe and effective manner.
Induction therapy
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The bias against transplanting morbidly obese patients extends further than just the potential technical difficulties in the operating room.
These high-risk patients have poor short-and long-term outcomes after transplantation, simplifying the decision to allocate limited organs to lower BMI patients. Three outcomes, in particular, substantiate this bias against morbidly obese candidates. First, morbidly obese recipients have significantly higher readmission rates, resulting in greater resource utilization. 21 These patients also have alarmingly high rates of wound complications after kidney transplantation, ranging from 15-44%, 3, 22, 23 which further increases posttransplantation readmission rates. 24 Our experience indicates that morbidly obese patients who undergo LSG have similar rates of 30-day and 1-year readmissions as compared to non-obese kidney transplant recipients. Postoperative infection rates were also similar between groups. Notably, readmissions secondary to renal dysfunction were lower within the post-LSG group. These results suggest that the advantages of surgical weight loss in morbidly obese patients with ESRD extend into posttransplantation resource expenditure.
Second, pretransplantation morbid obesity is an important risk factor for the development of NODAT. 25 The ramifications of NODAT are grave-this metabolic complication significantly increases risks of graft rejection, graft loss, and mortality. 25, 26 The reported incidence of NODAT ranges from 9.1% to 21% in the literature, and occurs much more frequently among morbidly obese kidney transplant recipients. [27] [28] [29] In the present study, the incidence of NODAT in our control group was 15.8%, which is consistent with the reported average. In comparison, none of the post-LSG patients developed NODAT during the follow-up period. Although there was no statistically significant difference in rates of NODAT between the two groups, these trends certainly warrant further investigation.
Third, DGF is a common and costly complication among morbidly obese recipients, occurring in one third of patients. 21, 23, [30] [31] [32] [33] [34] Comparatively, the reported incidence of DGF among all recipients is estimated at 21%. 35 The immediate consequences of DGF are ob- Given the current findings, we propose that morbidly obese patients with ESRD may benefit from referral to a specialized transplant/ bariatric surgery clinic. The advantages provided to these patients are 3-fold. First, this high-risk population is evaluated from a multidisciplinary approach, including dietary specialists, nephrologists, and bariatric and transplant surgeons. This allows all patients to be optimized from a medical and nutritional standpoint prior to LSG. Second, following bariatric surgery, these patients can be followed on a regular basis to determine when they become eligible for transplantation.
Third, previous studies have demonstrated that kidney transplantation in morbidly obese patients causes a 48% reduction in risk of death, despite increased risk of complications. Through pretransplantation LSG, morbidly obese patients can partake in the survival benefits of transplantation without increased complication rates.
Our study has some limitations that must be addressed. First, the retrospective nature of our study exposes it to selection and information biases. Second, the average follow-up period was significantly longer among the control group. Our follow-up period in the post-LSG group was nearly 2 years, which may be considered as long-term, but this interval is shorter than the average 5-year follow-up for our control patients. Third, the study is limited by small sample sizes. Greater numbers may be required to reveal further differences between nonmorbidly obese and post-LSG transplantation recipients. Fourth, the optimal control group for the current study may be matched, morbidly 
| CONCLUSIONS
This novel study investigates the impact of LSG on posttransplantation outcomes among morbidly obese patients using a direct-matched analysis. Our experience demonstrates that bariatric surgery reduces BMI among morbidly obese patients with ESRD patients, thereby improving their eligibility for transplantation without exposing them to harm. Furthermore, patients who undergo LSG to improve candidacy prior to kidney transplantation achieve excellent short-and longterm posttransplantation outcomes. Postoperative complications frequently experienced among obese recipients, such as DGF, NODAT, and obesity-associated conditions, are favorably impacted by surgical weight loss. These data highlight the many advantages of bariatric surgery in morbidly obese patients with ESRD.
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